0000899243-19-000956.txt : 20190110
0000899243-19-000956.hdr.sgml : 20190110
20190110160930
ACCESSION NUMBER: 0000899243-19-000956
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190108
FILED AS OF DATE: 20190110
DATE AS OF CHANGE: 20190110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novak Rodger
CENTRAL INDEX KEY: 0001682017
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 19520353
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-08
0
0001674416
CRISPR Therapeutics AG
CRSP
0001682017
Novak Rodger
C/O CRISPR THERAPEUTICS AG
BAARERSTRASSE 14
ZUG V8 CH-6300
V8
SWITZERLAND
1
1
0
0
President
Common Shares
2019-01-08
4
S
0
17310
35.09
D
1130697
D
Common Shares
2019-01-09
4
S
0
82690
35.01
D
1048007
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.105, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Michael Esposito, attorney-in-fact
2019-01-10